Tenax Therapeutics (TENX) Current Assets (2011 - 2026)
Tenax Therapeutics (TENX) posted quarterly Current Assets of $121.7 million for Q2 2026, up 14.93% year-over-year from $105.9 million in Q2 2025, and down 1.23% on a QoQ basis from $123.2 million in Q1 2026.
Tenax Therapeutics (TENX) Current Assets (2011 - 2026) Analysis & Trends
Tenax Therapeutics has reported Current Assets for 15 years, with the latest figure at $121.7 million in Q2 2026.
- Current Assets for Q2 2026 came in at $121.7 million, up 14.93% year-over-year; the trailing twelve-month figure through Jun 2026 was $121.7 million (up 14.93% YoY), and the FY2025 annual result was $104.2 million, up 7.8% from the prior year.
- Current Assets retreated to $121.7 million in Q2 2026, from $123.2 million in the prior quarter.
- Over five years, Current Assets peaked at $123.2 million in Q1 2026 and troughed at $3.2 million in Q4 2022.
- A 5-year average of $53.5 million and a median of $14.9 million in 2023 frame the typical range for Current Assets.
- The widest annual swing landed in 2022, when Current Assets tumbled 47.41%; it then jumped 897.17% in 2025.
- A 5-year view of Current Assets shows it stood at $3.2 million in 2022, then jumped by 264.16% to $11.7 million in 2023, then soared by 727.51% to $96.7 million in 2024, then climbed by 7.8% to $104.2 million in 2025, then grew by 16.73% to $121.7 million in 2026.
- Per Business Quant data, the three most recent Current Assets figures were $121.7 million in Q2 2026, $123.2 million in Q1 2026, and $104.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | 121.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 121.66 Mn |
| Mar 31, 2026 | 123.18 Mn |
| Dec 31, 2025 | 104.23 Mn |
| Sep 30, 2025 | 102.81 Mn |
| Jun 30, 2025 | 105.86 Mn |
| Mar 31, 2025 | 112.06 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Sep 30, 2024 | 99.78 Mn |
| Jun 30, 2024 | 10.62 Mn |
| Mar 31, 2024 | 14.46 Mn |
| Dec 31, 2023 | 11.68 Mn |
| Sep 30, 2023 | 11.88 Mn |
| Jun 30, 2023 | 14.04 Mn |
| Mar 31, 2023 | 15.26 Mn |
| Dec 31, 2022 | 3.21 Mn |
| Sep 30, 2022 | 4.51 Mn |
| Jun 30, 2022 | 8.10 Mn |
| Mar 31, 2022 | 3.46 Mn |
| Dec 31, 2021 | 5.69 Mn |
| Sep 30, 2021 | 8.58 Mn |